$96.5MSeries D, 24 June 2025
Round announced with first patient dosed in Phase 2 NEULARK trial of NEU-411
- Amount
- $96.5M
- Stage
- Series D
- Announced
- 24 June 2025
- Lead
- Westlake Village BioPartners
- Other investors
- SoftBank Vision Fund 2, Redmile Group, Kleiner Perkins
- Use of funds
- Round announced with first patient dosed in Phase 2 NEULARK trial of NEU-411
- Checked
- Announced by the company
- Sources
- Neuron23 raises $96.5M Series D businesswire.com
Neuron23 raises $96.5M Series D pulse2.com